BIO-key International (BKYI) Projected to Post Earnings on Wednesday

BIO-key International (NASDAQ:BKYI) is expected to be issuing its Q1 2026 results before the market opens on Wednesday, May 20th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $2.20 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 18, 2026 at 10:00 AM ET.

BIO-key International (NASDAQ:BKYI) last posted its quarterly earnings data on Tuesday, March 31st. The technology company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.51. BIO-key International had a negative return on equity of 67.43% and a negative net margin of 75.32%.The business had revenue of $1.24 million for the quarter, compared to analyst estimates of $2.20 million.

BIO-key International Stock Down 34.8%

BIO-key International stock opened at $3.46 on Wednesday. BIO-key International has a twelve month low of $3.40 and a twelve month high of $19.70. The stock’s fifty day simple moving average is $5.91 and its 200-day simple moving average is $6.59. The company has a current ratio of 1.26, a quick ratio of 1.13 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $3.77 million, a P/E ratio of -0.49 and a beta of 0.45.

Hedge Funds Weigh In On BIO-key International

An institutional investor recently raised its position in BIO-key International stock. Geode Capital Management LLC lifted its holdings in shares of BIO-key International Inc. (NASDAQ:BKYI) by 49.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,892 shares of the technology company’s stock after buying an additional 16,271 shares during the period. Geode Capital Management LLC owned approximately 0.45% of BIO-key International worth $26,000 at the end of the most recent quarter. Institutional investors own 26.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BIO-key International in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, BIO-key International has an average rating of “Sell”.

BIO-key International Company Profile

BIO-key International, Inc is a developer and provider of fingerprint biometric identity and access management solutions, serving enterprise and government customers. The company’s core offerings include a range of fingerprint readers and authentication software designed to verify user identity across physical and digital environments. By leveraging proprietary template-on-card and template-on-device technologies, BIO-key seeks to enhance security and streamline user access without reliance on traditional passwords.

In addition to hardware sensors, BIO-key delivers software platforms that integrate with existing IT infrastructures such as Microsoft Active Directory and major workforce management systems.